Fully Utilizing Closed Systems in Modern BioPharma Facilities
03rd September 2020 | 10:00 am EST/ 4:00pm CET | Lars Hovmand-Lyster, Senior Engineering Specialist in Novo Nordisk Global Project Office (GPO) Engineering Management Department |BOOK FREE SEAT FOR THIS WEBINAR
Build the roadmap to biopharmaceutical manufacturing and their partners in developing, assessing and verifying unit operations leading to an appropriate facility design that is “right classified”
Hear first-hand about this industry-developed document to understand the tools, steps and documents required to adequately risk assess and qualify modern facilities that make use of modular, closed technology
Learn how following a methodology results in significant gains in reducing the time to deliver the facilities and CAPEX and OPEX costs
Presented by Lars Hovmand-Lyster, Senior Engineering Specialist in Novo Nordisk Global Project Office (GPO) Engineering Management Department
Lars Hovmand-Lyster is the Senior Engineering specialist in Novo Nordisk Global Project Office (GPO) Engineering management department. Lars is the Quality Risk Management facilitator for product protection/closed Systems, contamination/cross contamination across Product Supply in Novo Nordisk. As well as Novo Nordisk Coordinator in BPOG Closed System in CNC work stream. Lars has had experience in different positions at Novo Nordisk since April 2001 covering QC laboratory, downstream processing, design and qualification.
Followed by Ross W. Acucena, Applications Director, Entegris LifeScience
Ross has 20 years of experience in pharma and biopharma working early in his career as process engineer and manufacturing leader for pharma and biopharma operations. The last 14 years having been spent in the supplier space working in various capacities in Technical Marketing, Regulatory Consulting, Product Development, and Business Leadership at MilliporeSigma, GE Biopharma ie. now Cytiva, and currently with Entegris Life Science. Ross’ work has focused primarily on sterile filtration applications and the successful implementation of single-use across within the bioprocess. Ross is passionate about helping the end-users in industry to achieve their objectives to improve human health. He has served industry efforts contributing to guidance documents, standards establishment, and provided seminars to end users and regulators on the topics of sterile filtration, extractables and leachables and single-use implementation. He holds an Bsc. In Chemical Engineering and MBA both from U-mass Lowell. He resides in Dunstable, Ma with his four sons
Sponsored by Entegris
Entegris, Inc. (NASDAQ: ENTG), As a global leader in advanced materials science, we have the expertise and determination to help solve your most advanced technology challenges. For more than 50 years, our singular mission has been to help customers utilize our advanced, science-based solutions to support a safer workplace; to innovate faster and more efficiently; and ultimately to transform the world.
No other company has both the expertise and experience to provide transformative new solutions for your processes. Our high-value and customizable solutions will help you solve your most difficult production challenges. Entegris supports large and small molecule production that reduces risk and increases your product purity, efficacy, and safety.
We provide reliable, quick-turn custom configurations that meet your complex performance demands. Our products offer customer-centric development, complete custom configuration with very short lead times. From pharmaceutical production, R&D labs, CROs, CDMOs to upstream, downstream, and buffer media prep, fine chemicals to drug substance storage and final filling, Entegris delivers high-performing solutions from small to full-scale processes.
Entegris is Headquartered in Billerica, MA, with a global infrastructure of manufacturing, service centers and research facilities in the United States, Canada, China, France, Germany, Israel, Japan, Malaysia, Singapore, South Korea and Taiwan.